RxDoctor Payments Data

Nandini Nagaraj, MD

Gastroenterology · Fort Worth, TXNPI 1285714071

Payments from drug & device makers

$2,133in general payments, 2019–2025

Across 113 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$948
  • Johnson & Johnson$181
  • Janssen Scientific Affairs, LLC$159
  • Madrigal Pharmaceuticals$124
  • Boston Scientific$121
  • Bristol Myers Squibb$119
  • plus $481 from 19 others

What the payments were for

  • Food & beverage$2,133100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,133 in reported general payments places this provider in the 35th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$99,054
Medicare patients
332
Services billed
1,137

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab14$380,147
Dupixent PenDupilumab11$84,097
LinzessLinaclotide31$19,699
SutabSod Sulf/Pot Chloride/Mag Sulf103$16,813
Mesalamine34$8,356
Omeprazole466$5,471
Famotidine357$4,573
Cholestyramine LightCholestyramine26$4,036
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates63$3,949
Esomeprazole Magnesium76$2,295
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag18$2,198
Sucralfate16$1,670
Pantoprazole Sodium117$1,258
Dicyclomine Hcl61$1,091
Hydrocortisone33$513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$181$380,14714 claims
AbbVieLinzess$948$19,69931 claims
Braintree Laboratories, Inc.Sutab, Suflave$28$19,011121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →